Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh
In developing countries, over 11 million children aged less than five years die each year, and nearly three quarters of these deaths result from infectious diseases. The World Health Organization (WHO) estimates that the death of at least four million of these children is linked to their lack of access to vaccines. Vaccines are highly effective against childhood diseases preventing an estimated three million deaths a year.
Every year Mellow Hope attends the government tender business of Hepatitis A Vaccine in Bangladesh. By virtue of Mellow Hope's high quality and competitive price, Mellow Hope's Hepatitis A Vaccine (MEVAC-A) has won the tenders in the last three consecutive years.
For 2009, Mellow Hope scheduled, and secured, and shipped the order. Mellow Hope is now preparing to participate for the 2010 tender.
As Mellow Hope has established a very solid foundation, strong track record and brand recognition in this region it is confident that it will also be successful with its 2010 tender as well.
In other company news, the company has completed certain filings on Pink Sheets, and brings attention with this release to those matters. One of the filings is the engagement letter of an SEC auditor as the company gears to complete its audit and become a reporting issuer. The second filing deals with certain activities of "oversold" and "sell only" campaign which affected HTDS. These are just one of many steps the company intends to take to protect its and its shareholders' interests.
Shortly the company will provide its followers with an update of behind the scenes measures and steps it is taking to address this issue. The company remains optimistic that just some the steps and measures it took will start to take effect and start trickling down as the market correct itself and the short covering begins.
Numerous updates to follow shortly on IP progress, the joint venture with the North American pharmaceutical company and other previously announced business matters.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact email@example.com; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
You May Also Like